Change-of-Direction Repeated Sprints in Adolescent Female Basketball Players
29. Juli 2026 aktualisiert von: Engin Güneş Atabaş, Pamukkale University
Effects of Changes of Direction on Repeated-Sprint Performance, Perceived Exertion, and Acute Cardiovascular Responses in Adolescent Female Basketball Players: A Randomized Crossover Study
The purpose of this randomized crossover study was to compare the acute effects of repeated-sprint protocols incorporating different numbers of 180-degree changes of direction in adolescent female basketball players.
Twenty participants completed three exercise conditions in a randomized, counterbalanced order: 10 × 15-m linear sprints, 10 × 15-m sprints incorporating one 180-degree change of direction, and 10 × 15-m sprints incorporating two 180-degree changes of direction.
Each sprint was followed by 30 seconds of passive recovery.
Sprint performance, perceived exertion, heart rate, peripheral oxygen saturation, and systolic and diastolic blood pressure were assessed.
The study examined whether increasing the number of changes of direction affected repeated-sprint performance and acute perceptual and cardiovascular responses.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Detaillierte Beschreibung
This was an acute, randomized, counterbalanced, three-condition crossover study in which each participant completed all experimental conditions and served as her own control.
Following a standardized warm-up, participants completed one of three repeated-sprint protocols during each experimental condition: 10 × 15-m linear sprints without a change of direction, 10 × 15-m sprints incorporating one 180-degree change of direction, or 10 × 15-m sprints incorporating two 180-degree changes of direction. A 30-second passive recovery period was provided between repetitions. Total sprint distance, number of repetitions, and recovery duration were standardized across the three conditions; only the number of changes of direction differed.
Sprint times were recorded using electronic timing gates. Best, average, and worst sprint times were determined, and sprint decrement and the change from best to worst performance were calculated. Rating of perceived exertion was recorded after each protocol. Heart rate, peripheral oxygen saturation, and systolic and diastolic blood pressure were assessed immediately before and after each condition.
The experimental conditions were compared to determine whether increasing the number of 180-degree changes of direction altered absolute repeated-sprint performance, performance maintenance, perceived exertion, or immediate cardiovascular responses.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
20
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Pamukkale
-
Denizli, Pamukkale, Türkei (türkiye), 20000
- Pamukkale University Sports Sciences and Technology Research and Application Center
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Female basketball players aged 16-18 years.
- Currently competing in the U16 or U18 basketball leagues in Denizli, Türkiye.
- At least two years of structured basketball training experience.
- Regular participation in at least three training sessions and one official match per week.
- No injury or illness that could prevent maximal sprint performance.
Exclusion Criteria:
- Reporting an injury before testing that could prevent maximal sprint performance.
- Failure to attend all testing sessions or complete all three experimental conditions.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Sequence 1: Linear-One-COD-Two-COD
Participants assigned to Sequence 1 completed the linear repeated-sprint condition during the first experimental session, the one-COD condition during the second session, and the two-COD condition during the third session.
Consecutive sessions were separated by at least 48 hours.
|
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m linear sprints without a change of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of 7.5 m of forward sprinting followed by one 180-degree change of direction and a 7.5-m return sprint.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of three consecutive 5-m sections and incorporated two 180-degree changes of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
|
|
Experimental: Sequence 2: One-COD-Two-COD-Linear
Participants assigned to Sequence 2 completed the one-COD repeated-sprint condition during the first experimental session, the two-COD condition during the second session, and the linear condition during the third session.
Consecutive sessions were separated by at least 48 hours.
|
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m linear sprints without a change of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of 7.5 m of forward sprinting followed by one 180-degree change of direction and a 7.5-m return sprint.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of three consecutive 5-m sections and incorporated two 180-degree changes of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
|
|
Experimental: Sequence 3: Two-COD-Linear-One-COD
Participants assigned to Sequence 3 completed the two-COD repeated-sprint condition during the first experimental session, the linear condition during the second session, and the one-COD condition during the third session.
Consecutive sessions were separated by at least 48 hours.
|
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m linear sprints without a change of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of 7.5 m of forward sprinting followed by one 180-degree change of direction and a 7.5-m return sprint.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
Following a standardized 20-minute dynamic warm-up, participants performed 10 maximal 15-m repeated sprints.
Each repetition consisted of three consecutive 5-m sections and incorporated two 180-degree changes of direction.
Each sprint began from a standing position 0.5 m behind the starting line and was recorded using electronic timing gates.
A 30-second passive recovery period was provided between repetitions, during which participants remained standing.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Average Sprint Time
Zeitfenster: During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The mean completion time of the 10 maximal 15-m sprint repetitions, recorded using Witty electronic timing gates and expressed in seconds.
The outcome was calculated separately for the linear, one-COD, and two-COD repeated-sprint conditions.
|
During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Best Sprint Time
Zeitfenster: During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The fastest completion time (lowest value) among the 10 maximal 15-m sprint repetitions, recorded using Witty electronic timing gates and expressed in seconds.
The outcome was determined separately for the linear, one-COD, and two-COD repeated-sprint conditions.
|
During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Worst Sprint Time
Zeitfenster: During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The slowest completion time (highest value) among the 10 maximal 15-m sprint repetitions, recorded using Witty electronic timing gates and expressed in seconds.
The outcome was determined separately for the linear, one-COD, and two-COD repeated-sprint conditions.
|
During the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sprint Decrement
Zeitfenster: Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The percentage reduction in performance across the 10 maximal sprint repetitions.
Sprint decrement was calculated separately for each experimental condition using the following formula: Sdec (%) = ([sum of the 10 sprint times / (best sprint time × 10)] - 1) × 100.
Higher values indicate a greater decline in repeated-sprint performance.
|
Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Worst-to-Best Decrement
Zeitfenster: Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
The percentage difference between the fastest and slowest sprint repetitions, calculated separately for each experimental condition using the following formula: [(worst sprint time - best sprint time) / best sprint time] × 100.
Higher values indicate a greater decline from the best to the worst performance.
|
Calculated from the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Rating of Perceived Exertion
Zeitfenster: Immediately after completion of the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Perceived exertion was assessed using the Borg category-ratio scale ranging from 0 to 10, where 0 represents rest and 10 represents maximal exertion.
Participants rated the overall difficulty of each completed repeated-sprint condition.
|
Immediately after completion of the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Heart Rate
Zeitfenster: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Heart rate was measured using a Soulfix fingertip pulse oximeter placed on the index finger of the left hand.
Values were recorded in beats per minute before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Peripheral Oxygen Saturation
Zeitfenster: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Peripheral oxygen saturation (SpO2) was measured using a Soulfix fingertip pulse oximeter placed on the index finger of the left hand.
Values were recorded as a percentage before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Systolic Blood Pressure
Zeitfenster: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Systolic blood pressure was measured on the left upper arm using an Omron M2 Essential automated digital blood-pressure monitor.
Values were recorded in millimeters of mercury (mmHg) before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
|
Diastolic Blood Pressure
Zeitfenster: Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Diastolic blood pressure was measured on the left upper arm using an Omron M2 Essential automated digital blood-pressure monitor.
Values were recorded in millimeters of mercury (mmHg) before and immediately after each repeated-sprint condition.
|
Immediately before and immediately after the repeated-sprint protocol in Sessions 1, 2, and 3 on Study Days 1, 3, and 5, respectively.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Engin Güneş Atabaş, PhD, Pamukkale Üniversitesi
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
2. Mai 2026
Primärer Abschluss (Tatsächlich)
21. Mai 2026
Studienabschluss (Tatsächlich)
21. Mai 2026
Studienanmeldedaten
Zuerst eingereicht
22. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
22. Juli 2026
Zuerst gepostet (Tatsächlich)
27. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
30. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
29. Juli 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- PAU-COD-RSA-2026-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Beschreibung des IPD-Plans
Individual participant data will not be publicly shared because participant consent did not include public data sharing and the dataset contains information from adolescent participants.
De-identified aggregate data may be made available from the corresponding author upon reasonable request and subject to institutional and ethical approval.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .